Kazia Therapeutics’ (ASX: KZA) oncology drug paxalisib continues to generate positive trial data (w/ James Garner)

Kazia Therapeutics (ASX: KZA) CEO James Garner joins Small Caps to discuss the company’s ongoing development of its lead drug paxalisib, which recently generated positive interim data in a phase one clinical trial for treating brain metastases. The drug is primarily being developed to treat glioblastoma, which is the most aggressive form of primary brain cancer in adults. However, Kazia is actively studying paxalisib in various other forms of brain cancer and has secured US FDA orphan drug and fast-track designations for glioblastoma. Articles: https://smallcaps.com.au/kazia-therapeutics-reveals-response-rate-interim-data-brain-metastases-drug-trial/https://smallcaps.com.au/world-leading-brain-cancer-experts-kazia-therapeutics-new-scientific-advisory-board/https://smallcaps.com.au/kazia-therapeutics-awarded-us-fda-rare-drug-designation-paxalisib-childhood-brain-cancer/ For more information on Kazia Therapeutics: https://smallcaps.com.au/stocks/KZA/See omnystudio.com/listener for privacy information.